Zacks Investment Research upgraded shares of Fluidigm Corp. (NASDAQ:FLDM) from a sell rating to a hold rating in a report published on Wednesday.

According to Zacks, “Fluidigm Corporation operates as a biotech tools company that creates microfluidic-based chips and instrumentation for biological research. Products offered by the Company include BioMark HD System- a real time PCR; EP1 system for SNP genotyping; Access Array System-an Integrated Fluidic Circuit (IFC); TOPAZ system for protein crystallography; Dynamic Array integrated fluidic circuits (IFCs); and Access Array Assay Design Services. The Company’s products find its application in Gene Expression, Single-Cell Gene Expression, SNP Genotyping, Targeted Resequencing, Sample Quantitation, Copy Number Variation and Protein Crystallization. Fluidigm Corporation is based in San Francisco, California. “

Other research analysts have also recently issued reports about the company. Cantor Fitzgerald cut their price objective on Fluidigm Corp. from $13.00 to $11.00 and set a buy rating for the company in a report on Friday, August 5th. Deutsche Bank AG started coverage on Fluidigm Corp. in a report on Wednesday, June 1st. They set a buy rating for the company. Finally, Mizuho lifted their price objective on Fluidigm Corp. from $11.00 to $12.00 and gave the company a buy rating in a report on Friday, August 5th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of $13.67.

Shares of Fluidigm Corp. (NASDAQ:FLDM) opened at 8.08 on Wednesday. The firm’s market capitalization is $234.61 million. Fluidigm Corp. has a one year low of $4.84 and a one year high of $12.09. The firm has a 50-day moving average of $9.31 and a 200-day moving average of $9.08.

Fluidigm Corp. (NASDAQ:FLDM) last issued its earnings results on Thursday, August 4th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.58) by $0.06. The firm earned $28.20 million during the quarter, compared to the consensus estimate of $29.62 million. Fluidigm Corp. had a negative return on equity of 45.68% and a negative net margin of 52.04%. The firm’s revenue for the quarter was down 1.5% compared to the same quarter last year. During the same period last year, the business earned ($0.53) earnings per share. On average, equities analysts predict that Fluidigm Corp. will post ($2.32) earnings per share for the current fiscal year.

Hedge funds have recently made changes to their positions in the stock. Cookson Peirce & Co. Inc. acquired a new stake in shares of Fluidigm Corp. during the second quarter worth $123,000. BlackRock Advisors LLC raised its stake in shares of Fluidigm Corp. by 10.4% in the second quarter. BlackRock Advisors LLC now owns 14,529 shares of the company’s stock worth $131,000 after buying an additional 1,373 shares during the last quarter. Parametric Portfolio Associates LLC raised its stake in shares of Fluidigm Corp. by 89.3% in the second quarter. Parametric Portfolio Associates LLC now owns 21,070 shares of the company’s stock worth $190,000 after buying an additional 9,939 shares during the last quarter. Stoneridge Investment Partners LLC purchased a new stake in shares of Fluidigm Corp. during the second quarter worth approximately $220,000. Finally, AQR Capital Management LLC raised its stake in shares of Fluidigm Corp. by 58.8% in the second quarter. AQR Capital Management LLC now owns 25,187 shares of the company’s stock worth $227,000 after buying an additional 9,324 shares during the last quarter. Institutional investors own 93.33% of the company’s stock.

About Fluidigm Corp.

Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.

5 Day Chart for NASDAQ:FLDM

Get a free copy of the Zacks research report on Fluidigm Corp. (FLDM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Fluidigm Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corp. and related companies with Analyst Ratings Network's FREE daily email newsletter.